Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Merck”

Evaluation of a Vaccine Chatbot on HPV Vaccine Confidence and HesitancyNot Yet Recruiting
NCT07200570NAUpdated Aug 4, 2026
Sponsor: Fudan University
HPV Vaccine
A Study of Calderasib (MK-1084) in Participants With Hepatic Impairment and Healthy Volunteers (MK-1084-017)Completed
NCT07219550Phase 1Updated Aug 4, 2026
Sponsor: Merck Sharp & Dohme LLC
Healthy · Hepatic Impairment
United States
Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic CancerRecruiting
NCT05132504Phase 2Updated Aug 4, 2026
Sponsor: Baylor College of Medicine
Pancreatic Ductal Adenocarcinoma
United States
A Clinical Trial of MK-8527 and Rifampin in Adult Participants With Latent Tuberculosis Infection (MK-8527-019)Not Yet Recruiting
NCT07600775Phase 1Updated Aug 3, 2026
Sponsor: Merck Sharp & Dohme LLC
Human Immunodeficiency Virus (HIV) · HIV Pre-Exposure Prophylaxis
NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)Recruiting
NCT06081244Phase 3Updated Aug 3, 2026
Sponsor: Women's Cancer Study Group GmbH
Triple Negative Breast Cancer
Germany
A Clinical Trial in Healthy Participants to Study the Effect of a Single Dose of MK-8527 on Levels of Methadone (MK-8527-020)Active Not Recruiting
NCT07528508Phase 1Updated Aug 3, 2026
Sponsor: Merck Sharp & Dohme LLC
Healthy
United States
Effect of Hepatic Impairment on the Pharmacokinetics of MirdametinibRecruiting
NCT06997276Phase 1Updated Aug 3, 2026
Sponsor: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Healthy · Hepatic Impairment
United States
A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)Recruiting
NCT07227402Phase 3Updated Aug 3, 2026
Sponsor: Merck Sharp & Dohme LLC
Renal Cell Carcinoma
United States, Argentina, Australia, Austria, Belgium +18 more
Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)Active Not Recruiting
NCT06305754Phase 3Updated Aug 3, 2026
Sponsor: Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer (NSCLC)
United States, Argentina, Canada, China, Colombia +14 more
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)Recruiting
NCT04924075Phase 2Updated Aug 3, 2026
Sponsor: Merck Sharp & Dohme LLC
Pheochromocytoma/Paraganglioma · Pancreatic Neuroendocrine Tumor · Von Hippel-Lindau Disease · Advanced Gastrointestinal Stromal Tumor
United States, Australia, Canada, Chile, China +17 more
Clinical Study of MK-4884 in Participants With Advanced or Metastatic Solid Tumors (MK-4884-001)Recruiting
NCT07600749Phase 1Updated Aug 3, 2026
Sponsor: Merck Sharp & Dohme LLC
Malignant Neoplasm
United States, Israel, Japan, Switzerland
A Clinical Trial of MK-1406 in Healthy Participants (MK-1406-008)Not Yet Recruiting
NCT07743151Phase 1Updated Aug 3, 2026
Sponsor: Merck Sharp & Dohme LLC
Healthy
A Study of Vericiguat in People With Breast Cancer and Cancer Therapy-Related Cardiac DysfunctionActive Not Recruiting
NCT05806138Phase 2Updated Aug 3, 2026
Sponsor: Memorial Sloan Kettering Cancer Center
Breast Cancer · Cardiac Dysfunction
United States
Surveillance of Non-invasive Streptococcus Pneumoniae Infections in BelgiumCompleted
NCT04447521N/AUpdated Aug 3, 2026
Sponsor: Sciensano
Pneumonia · Otitis Media · Sinusitis Bacterial
Belgium
Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)Active Not Recruiting
NCT03765918Phase 3Updated Jul 31, 2026
Sponsor: Merck Sharp & Dohme LLC
Head and Neck Neoplasms
United States, Argentina, Australia, Austria, Belgium +19 more
A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid TumorsRecruiting
NCT06983743Phase 1Updated Jul 31, 2026
Sponsor: Erasca, Inc.
Metastatic Solid Tumors
United States
A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)Recruiting
NCT05067283Phase 1Updated Jul 31, 2026
Sponsor: Merck Sharp & Dohme LLC
Advanced Solid Tumors
United States, Argentina, Australia, Canada, Chile +16 more
A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal CancerActive Not Recruiting
NCT05217446Phase 2Updated Jul 31, 2026
Sponsor: Pfizer
Metastatic Colorectal Cancer
United States, Australia, Belgium, Canada, Czechia +10 more
A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004)Recruiting
NCT07363590Phase 1Updated Jul 31, 2026
Sponsor: Merck Sharp & Dohme LLC
Systemic Lupus Erythematosus · Rheumatoid Arthritis
Australia, Belgium, China, Colombia, Georgia +5 more
KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)Recruiting
NCT07252739Phase 2Updated Jul 30, 2026
Sponsor: Merck Sharp & Dohme LLC
Malignant Neoplasm
United States, Chile, China, Finland, Greece +8 more
KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)Recruiting
NCT04165798N/AUpdated Jul 30, 2026
Sponsor: Merck Sharp & Dohme LLC
Carcinoma, Non-Small-Cell Lung
United States, Hungary, Israel, Italy, Poland +4 more
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)Active Not Recruiting
NCT06710132Phase 1, Phase 2Updated Jul 30, 2026
Sponsor: EMD Serono Research & Development Institute, Inc.
Solid Tumors · Gastric Cancer · Non-Small Cell Lung Cancer (NSCLC) · Pancreatic Cancer
United States, Australia, Austria, China, France +5 more
Interpersonal Communication Training and Vaccination Workflow Training Alone and in Combination to Improve Communication and Recommendations About HPV Vaccination in Pharmacies, IMPACT HPV TrialRecruiting
NCT06926062NAUpdated Jul 30, 2026
Sponsor: Fred Hutchinson Cancer Center
Human Papillomavirus-Related Carcinoma
United States
Phase 2 DoceRamPem for Patients With Metastatic or Recurrent NSCLC Who Progressed on Platinum-Doublet and PD-1/PD-L1 BlockadeActive Not Recruiting
NCT04340882Phase 2Updated Jul 30, 2026
Sponsor: Emory University
Metastatic Non-Small Lung Cell Cancer · Recurrent Non-Small Lung Cell Cancer · Stage IV Lung Cancer AJCC v8 · Stage IVA Lung Cancer AJCC v8
United States
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)Recruiting
NCT04165070Phase 1, Phase 2Updated Jul 30, 2026
Sponsor: Merck Sharp & Dohme LLC
Carcinoma, Non-Small-Cell Lung
United States, Hungary, Israel, Italy, Poland +4 more

Previous page Next page